This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Safety and Total Mortality Issues

Scott M. Grundy, MD, PhD

Arch Intern Med. 1992;152(7):1369-1371.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT)^1,2 was a landmark clinical trial that showed that lowering of the serum cholesterol level by cholestyramine therapy significantly decreased the risk for coronary heart disease (CHD). This trial provided the critical proof for the cholesterol-CHD hypothesis and, thereby, made possible the initiation of the National Cholesterol Education Program. A reduction in CHD rates by cholestyramine therapy was not accompanied by demonstrable serious side effects during the 7-year study period. However, in spite of a reduction in both new-onset CHD and deaths from CHD by cholestyramine treatment, there was not a statistically significant decrease in total mortality; this was because an apparent increase in trauma mortality offset the decrease in CHD deaths. The apparent increase in trauma mortality, it must be noted, was not statistically significant. Cholestyramine therapy in this trial also did not significantly predispose to tumor formation. Although total . . . [Full Text PDF of this Article]

Author Affiliations
Center for Human Nutrition Department of Clinical Nutrition University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75235-9052

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?